Pharmaceutical Executive December 2, 2024
Under terms of the deal, Roche will gain access to Poseida’s pipeline, including P-BCMA-ALLO1, an allogeneic CAR T-cell therapy for multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR T-cell therapy in early trials for B-cell malignancies and autoimmune diseases.
Roche has agreed to acquire Poseida Therapeutics, a biopharmaceutical company specializing in donor-derived allogeneic chimeric antigen receptor (CAR) T-cell therapies for oncology, immunology, and autoimmune diseases. According to the company, Roche will gain access to Poseida’s pipeline, including key programs such as P-BCMA-ALLO1, an allogeneic CAR T- cell therapy for multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR T-cell therapy in early trials for B-cell malignancies and autoimmune diseases. The deal comes after the companies first started collaborating in 2022. The acquisition also...
Today's Sponsors
Today's Sponsor